December 7, 2017, SAN ANTONIO – StemBioSys Inc. announced that it has entered into an agreement with Caltag Medsystems Ltd. to distribute and market StemBioSys products. Caltag will distribute StemBioSys products in the European Union. [Read more…]
Pluristem Gets Accelerated Approval Pathways in Top 3 Healthcare Markets – U.S., Europe, Japan
Cell therapy was recently described as “One of the most promising new fields of science and medicine,” by FDA Commissioner Scott Gottlieb. He went on to state that cell therapy and regenerative medicine “…hold significant promise for transformative and potentially curative treatments for some of humanity’s most troubling and intractable maladies.” In the FDA statement issued August 28th, Gottlieb also revealed that the U.S. regulator is looking improve upon its approval process for cell therapies. [Read more…]
Ncardia and Evotec Enter Licencing Agreement for Disease Modelling Using iPS Cells
December 04, 2017, GOSSELIES, Belgium—Ncardia, a leader in standardised, validated iPSC assays for safety, phenotypic screening and disease modeling, announced today that they entered into a global non-exclusive IP licensing agreement with Evotec (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809). The financial terms of the agreements are not disclosed. [Read more…]
Does Your Stem Cell Market Intelligence Utilize Futuristic Techniques?
2017 has never seen more opportunity for analysis of data, as the total global amount of data is now estimated to be 1.2 zettabytes.
Therefore, techniques for managing analysis of data must dynamically evolve.
While you may not understand the precise meaning of research terms such as meta-analysis, algorithmic analysis, or predictive trend analysis, it is important to ask yourself, are you embracing new and evolving methods for sourcing market data?
Futuristic (Definition): “Having or involving very modern technology or design”
Whether you are conducting your own market research or outsourcing it to a third-party, you should get clear answers to the following: [Read more…]
Pluristem Granted Key U.S. Patent for Skeletal Muscle Regeneration – a Meaningful Asset Ahead of Upcoming Phase III Femoral Neck Fracture Study
- Patent relates to the use of Mesenchymal Stem Cells (MSCs) for muscle regeneration following muscle injury
- Pivotal Phase III study to take place in U.S. and Europe to support recovery from hip fracture
HAIFA, Israel, Nov. 22, 2017 (GLOBE NEWSWIRE) — Pluristem Therapeutics Inc. (NASDAQ:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, announced today that the U.S. Patent and Trademark Office (USPTO) has issued a patent titled, “Skeletal muscle regeneration using mesenchymal system cells.” This key patent, which has already been granted in Europe, Hong Kong and Israel, addresses the use of MSCs for skeletal muscle regeneration used either directly after, or shortly after, post-surgical muscle injury.
The Company received positive feedback from the U.S. Food and Drug Administration (FDA) and the European Medicine Agency (EMA) for the proposed study design and endpoints of its Phase III trial for the treatment of muscle recovery following arthroplasty for hip fracture. This planned study was recently awarded an $8.7 million grant by the Horizon 2020 program, the European Union’s largest research and innovation program. If successful, Pluristem plans to use the study results to achieve marketing approval in both the U.S. and Europe. [Read more…]
- « Previous Page
- 1
- …
- 120
- 121
- 122
- 123
- 124
- …
- 201
- Next Page »